Dataset Information

Mass spectrometry analysis identifies DESI2 as a novel component of the JAK2-V617F complex

ABSTRACT: This experiment employs an analytical platform based on the Ultimate 3000 nano ultra-high-performance liquid chromatography system coupled to the Q Exactive Plus high-resolution mass spectrometer, combined with database search software, to conduct qualitative (or relative quantitative) analysis of proteins in samples from different experimental groups. The resulting protein list reflects the types and relative abundances of proteins detected in this mass spectrometry analysis.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Cell

DISEASE(S): Acute Leukemia

SUBMITTER: Mei Husheng

LAB HEAD: Jing Yang

PROVIDER: PXD065727 | Pride | 2026-02-09

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20240518-R24550-IP-JAK2_calibrated.mzML	Mzml
	20240518-R24550-IP-JAK2_uncalibrated.mzML	Mzml
	20240518-R24550-IgG_calibrated.mzML	Mzml
	20240518-R24550-IgG_uncalibrated.mzML	Mzml
	Q9BSY9.fasta	Fasta

Items per page:

1 - 5 of 14

Publications

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias.

Mei Husheng H Wen Wuqiang W Zhang Wenjun W Zhang Shujing S Sun Ting T Li Guiming G Zhang Jing J Qi Shuang S Zhou Jie J Li Bing B Zhao Yunshuo Y Chen Xiaotong X Li Bowen B Xue Yiying Y Lu Wang W Sun Yanli Y Wang Jingyao J Shan Hengyue H Zhang Shengzhe S Huang Yushan Y Chen Yisa Y Wang Wenchao W Liu Qingsong Q Lu Wenchao W Tan Li L Ding Yi Y Fu Jianfei J Long Jun J Zhang Lei L Zhao Baobing B Liang Aibin A Jiang Baishan B Yang Jing J

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 20251203 7

The JAK2-V617F mutation is the most common genetic alteration in myeloproliferative neoplasms (MPN), which can progress to secondary acute myeloid leukemia (sAML), a chemotherapy-resistant disease with limited treatment options and a poor prognosis. Although the JAK1/2 inhibitor Ruxolitinib is clinically approved, its efficacy is limited by toxicity to normal cells and the development of drug resistance. Here, the deSUMOylase DESI2 is identified as a novel component of the JAK2-V617F complex by ...[more]

PMID: 41332324

Dataset Information

Mass spectrometry analysis identifies DESI2 as a novel component of the JAK2-V617F complex

Dataset's files

Publications

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

LC-MS-Based Quantitative Proteomic Profiling Reveals WWQ-03-012-Induced Alterations in Protein Expression of Human HEL Cells
2026-02-09 | PXD065708 | Pride

Analysis of circ101093 binding proteins in A549 cells after RNA pull-down.
2022-05-20 | PXD025575 | Pride

Proteomic and phosphoproteomic analyses for HT-29
2025-02-28 | PXD058218 | Pride

BioID to identify RRas2-binding proteins.
2025-06-30 | PXD062082 | Pride

Identification of STAMBP-interacting proteins by IP-MS screening.
2026-02-13 | PXD071368 | Pride

Identification of host interactors of Brucella BT4E effector proteins by Flag-tag affinity purification coupled with LC-MS/MS in HEK293T cells
2026-02-13 | PXD068987 | Pride

LC-MS by circHIPK3 probe method in human oral submucosal fibroblasts
2025-05-13 | PXD062842 | Pride

Proteomics analysis of Control and Palbociclib-treated HeLa cells
2025-12-04 | PXD070997 | Pride

Phospho-proteomic profile of control and Palbociclib-treated HeLa cells
2025-12-04 | PXD071048 | Pride

Protein relative quantitative analysis based on parallel reaction detection (PRM)
2025-07-18 | PXD058173 | Pride